IMMUNE NETWORK

  • 제16권1호
  • /
  • Pages.44-51
  • /
  • 2016
  • /
  • 1598-2629(pISSN)
  • /
  • 2092-6685(eISSN)
대한면역학회 (The Korean Association of Immunobiologists)
권호 표지
DOI QR코드

DOI QR Code

Dendritic Cell-based Immunotherapy for Rheumatoid Arthritis: from Bench to Bedside

  • Md. Selim Ahmed (Department of Biological Science, Sungkyunkwan University) ;
  • Yong-Soo Bae (Department of Biological Science, Sungkyunkwan University)
  • 투고 : 2015.12.21
  • 심사 : 2016.02.02
  • 발행 : 2016.02.29
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Dendritic cells (DCs) are professional antigen presenting cells, and play an important role in the induction of antigen-specific adaptive immunity. However, some DC populations are involved in immune regulation and immune tolerance. These DC populations are believed to take part in the control of immune exaggeration and immune disorder, and maintain immune homeostasis in the body. Tolerogenic DCs (tolDCs) can be generated in vitro by genetic or pharmacological modification or by controlling the maturation stages of cytokine-derived DCs. These tolDCs have been investigated for the treatment of rheumatoid arthritis (RA) in experimental animal models. In the last decade, several in vitro and in vivo approaches have been translated into clinical trials. As of 2015, three tolDC trials for RA are on the list of ClinicalTrial.gov (www.clinicaltrials.gov). Other trials for RA are in progress and will be listed soon. In this review, we discuss the evolution of tolDC-based immunotherapy for RA and its limitations and future prospects.

키워드

과제정보

This work was supported by the Bio & Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean Ministry of Education Science and Technology (2012M3A9B402826).

참고문헌

  1. Hilkens, C. M., and J. D. Isaacs. 2013. Tolerogenic dendritic cell therapy for rheumatoid arthritis: where are we now? Clin. Exp. Immunol. 172: 148-157. https://doi.org/10.1111/cei.12038
  2. Choy, E. H., A. F. Kavanaugh, and S. A. Jones. 2013. The problem of choice: current biologic agents and future prospects in RA. Nat. Rev. Rheumatol. 9: 154-163. https://doi.org/10.1038/nrrheum.2013.8
  3. Singh, J. A., R. Christensen, G. A. Wells, M. E. Suarez-Almazor, R. Buchbinder, M. A. Lopez-Olivo, G. E. Tanjong, and P. Tug-well. 2009. Biologics for rheumatoid arthritis: an overview of Cochrane reviews. Cochrane Database Syst. Rev. CD007848.
  4. Stoop, J. N., J. H. Robinson, and C. M. Hilkens. 2011. Developing tolerogenic dendritic cell therapy for rheumatoid arthritis: what can we learn from mouse models? Ann. Rheum. Dis. 70: 1526-1533. https://doi.org/10.1136/ard.2011.151654
  5. Steinman, R. M. 2012. Decisions about dendritic cells: past, present, and future. Annu. Rev. Immunol. 30: 1-22. https://doi.org/10.1146/annurev-immunol-100311-102839
  6. Steinman, R. M., and M. C. Nussenzweig. 2002. Avoiding horror autotoxicus: the importance of dendritic cells in peripheral T cell tolerance. Proc. Natl. Acad. Sci. U. S. A. 99: 351-358. https://doi.org/10.1073/pnas.231606698
  7. Jonuleit, H., E. Schmitt, K. Steinbrink, and A. H. Enk. 2001. Dendritic cells as a tool to induce anergic and regulatory T cells. Trends Immunol. 22: 394-400. https://doi.org/10.1016/S1471-4906(01)01952-4
  8. Yamazaki, S., K. Inaba, K. V. Tarbell, and R. M. Steinman. 2006. Dendritic cells expand antigen-specific Foxp3+ CD25+ CD4+ regulatory T cells including suppressors of alloreactivity. Immunol. Rev. 212: 314-329. https://doi.org/10.1111/j.0105-2896.2006.00422.x
  9. Roncarolo, M. G., M. K. Levings, and C. Traversari. 2001. Differentiation of T regulatory cells by immature dendritic cells. J. Exp. Med. 193: F5-F9. https://doi.org/10.1084/jem.193.2.F5
  10. Voigtlander, C., S. Rossner, E. Cierpka, G. Theiner, C. Wiethe, M. Menges, G. Schuler, and M. B. Lutz. 2006. Dendritic cells matured with TNF can be further activated in vitro and after subcutaneous injection in vivo which converts their tolerogenicity into immunogenicity. J. Immunother. 29: 407-415. https://doi.org/10.1097/01.cji.0000210081.60178.b4
  11. Kleindienst, P., C. Wiethe, M. B. Lutz, and T. Brocker. 2005. Simultaneous induction of CD4 T cell tolerance and CD8 T cell immunity by semimature dendritic cells. J. Immunol. 174: 3941-3947. https://doi.org/10.4049/jimmunol.174.7.3941
  12. Rutella, S., S. Danese, and G. Leone. 2006. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 108: 1435-1440. https://doi.org/10.1182/blood-2006-03-006403
  13. Harden, J. L., and N. K. Egilmez. 2012. Indoleamine 2,3-dioxygenase and dendritic cell tolerogenicity. Immunol. Invest 41: 738-764. https://doi.org/10.3109/08820139.2012.676122
  14. Quaratino, S., L. P. Duddy, and M. Londei. 2000. Fully competent dendritic cells as inducers of T cell anergy in autoimmunity. Proc. Natl. Acad. Sci. U. S. A. 97: 10911-10916. https://doi.org/10.1073/pnas.190204697
  15. Lutz, M. B. 2012. Therapeutic potential of semi-mature dendritic cells for tolerance induction. Front. Immunol. 3: 123.
  16. Bianco, N. R., S. H. Kim, M. A. Ruffner, and P. D. Robbins. 2009. Therapeutic effect of exosomes from indoleamine 2,3-dioxygenase-positive dendritic cells in collagen-induced arthritis and delayed-type hypersensitivity disease models. Arthritis Rheum. 60: 380-389. https://doi.org/10.1002/art.24229
  17. Kim, S. H., S. Kim, T. J. Oligino, and P. D. Robbins. 2002. Effective treatment of established mouse collagen-induced arthritis by systemic administration of dendritic cells genetically modified to express FasL. Mol. Ther. 6: 584-590. https://doi.org/10.1016/S1525-0016(02)90712-4
  18. Yang, J., S. M. Bernier, T. E. Ichim, M. Li, X. Xia, D. Zhou, X. Huang, G. H. Strejan, D. J. White, R. Zhong, and W. P. Min. 2003. LF15-0195 generates tolerogenic dendritic cells by suppression of NF-kappaB signaling through inhibition of IKK activity. J. Leukoc. Biol. 74: 438-447. https://doi.org/10.1189/jlb.1102582
  19. Menges, M., S. Rossner, C. Voigtlander, H. Schindler, N. A. Kukutsch, C. Bogdan, K. Erb, G. Schuler, and M. B. Lutz. 2002. Repetitive injections of dendritic cells matured with tumor necrosis factor alpha induce antigen-specific protection of mice from autoimmunity. J. Exp. Med. 195: 15-21. https://doi.org/10.1084/jem.20011341
  20. Lim, D. S., M. S. Kang, J. A. Jeong, and Y. S. Bae. 2009. Semi-mature DC are immunogenic and not tolerogenic when inoculated at a high dose in collagen-induced arthritis mice. Eur. J. Immunol. 39: 1334-1343. https://doi.org/10.1002/eji.200838987
  21. Sakaguchi, S. 2000. Regulatory T cells: key controllers of immunologic self-tolerance. Cell 101: 455-458. https://doi.org/10.1016/S0092-8674(00)80856-9
  22. Bach, J. F. 2003. Regulatory T cells under scrutiny. Nat. Rev. Immunol. 3: 189-198. https://doi.org/10.1038/nri1026
  23. Fontenot, J. D., M. A. Gavin, and A. Y. Rudensky. 2003. Foxp3 programs the development and function of CD4+CD25+ regulatory T cells. Nat. Immunol. 4: 330-336. https://doi.org/10.1038/ni904
  24. Khattri, R., T. Cox, S. A. Yasayko, and F. Ramsdell. 2003. An essential role for Scurfin in CD4+CD25+ T regulatory cells. Nat. Immunol. 4: 337-342.
  25. Buckner, J. H. 2010. Mechanisms of impaired regulation by CD4(+)CD25(+)FOXP3(+) regulatory T cells in human autoimmune diseases. Nat. Rev. Immunol. 10: 849-859. https://doi.org/10.1038/nri2889
  26. Thomson, A. W. and P. D. Robbins. 2008. Tolerogenic dendritic cells for autoimmune disease and transplantation. Ann. Rheum. Dis. 67 Suppl 3: iii90-iii96.
  27. Zheng, J., H. Y. Jiang, J. Li, H. C. Tang, X. M. Zhang, X. R. Wang, J. T. Du, H. B. Li, and G. Xu. 2012. MicroRNA-23b promotes tolerogenic properties of dendritic cells in vitro through inhibiting Notch1/NF-kappaB signalling pathways. Allergy 67: 362-370. https://doi.org/10.1111/j.1398-9995.2011.02776.x
  28. Stumpfova, Z., R. Hezova, A. C. Meli, O. Slaby, and J. Michalek. 2014. MicroRNA profiling of activated and tolerogenic human dendritic cells. Mediators Inflamm. 2014: 259689.
  29. Valencia, J., C. Hernandez-Lopez, V. G. Martinez, L. Hidalgo, A. G. Zapata, A. Vicente, A. Varas, and R. Sacedon. 2011. Wnt5a skews dendritic cell differentiation to an unconventional phenotype with tolerogenic features. J. Immunol. 187: 4129-4139. https://doi.org/10.4049/jimmunol.1101243
  30. Zhu, B., T. Buttrick, R. Bassil, C. Zhu, M. Olah, C. Wu, S. Xiao, W. Orent, W. Elyaman, and S. J. Khoury. 2013. IL-4 and retinoic acid synergistically induce regulatory dendritic cells expressing Aldh1a2. J. Immunol. 191: 3139-3151. https://doi.org/10.4049/jimmunol.1300329
  31. Steinbrink, K., M. Wolfl, H. Jonuleit, J. Knop, and A. H. Enk. 1997. Induction of tolerance by IL-10-treated dendritic cells. J. Immunol. 159: 4772-4780. https://doi.org/10.4049/jimmunol.159.10.4772
  32. Yarilin, D., R. Duan, Y. M. Huang, and B. G. Xiao. 2002. Dendritic cells exposed in vitro to TGF-beta1 ameliorate experimental autoimmune myasthenia gravis. Clin. Exp. Immunol. 127: 214-219. https://doi.org/10.1046/j.1365-2249.2002.01748.x
  33. Boks, M. A., J. R. Kager-Groenland, M. S. Haasjes, J. J. Zwaginga, S. M. van Ham, and B. A. ten. 2012. IL-10-generated tolerogenic dendritic cells are optimal for functional regulatory T cell induction--a comparative study of human clinical-applicable DC. Clin. Immunol. 142: 332-342. https://doi.org/10.1016/j.clim.2011.11.011
  34. Turnquist, H. R., G. Raimondi, A. F. Zahorchak, R. T. Fischer, Z. Wang, and A. W. Thomson. 2007. Rapamycin-conditioned dendritic cells are poor stimulators of allogeneic CD+ T cells, but enrich for antigen-specific Foxp3+ T regulatory cells and promote organ transplant tolerance. J. Immunol. 178: 7018-7031. https://doi.org/10.4049/jimmunol.178.11.7018
  35. Pothoven, K. L., T. Kheradmand, Q. Yang, J. L. Houlihan, H. Zhang, M. Degutes, S. D. Miller, and X. Luo. 2010. Rapamycin-conditioned donor dendritic cells differentiate CD4CD25Foxp3 T cells in vitro with TGF-beta1 for islet transplantation. Am. J. Transplant. 10: 1774-1784. https://doi.org/10.1111/j.1600-6143.2010.03199.x
  36. Salazar, L., O. Aravena, P. Abello, A. Escobar, J. Contreras-Levicoy, N. Rojas-Colonelli, D. Catalan, A. Aguirre, R. Zuniga, B. Pesce, C. Gonzalez, R. Cepeda, M. Cuchacovich, M. C. Molina, F. Salazar-Onfray, M. Delgado, R. E. Toes, and J. C. Aguillon. 2008. Modulation of established murine collagen-induced arthritis by a single inoculation of short-term lipopolysaccharide-stimulated dendritic cells. Ann. Rheum. Dis. 67: 1235-1241.
  37. van der, K. D., E. Latz, J. F. Brouwers, Y. C. Kruize, M. Schmitz, E. A. Kurt-Jones, T. Espevik, E. C. de Jong, M. L. Kapsenberg, D. T. Golenbock, A. G. Tielens, and M. Yazdanbakhsh. 2002. A novel host-parasite lipid cross-talk. Schistosomal lyso-phosphatidylserine activates toll-like receptor 2 and affects immune polarization. J. Biol. Chem. 277: 48122-48129. https://doi.org/10.1074/jbc.M206941200
  38. Maldonado, R. A., and U. H. von Andrian. 2010. How tolerogenic dendritic cells induce regulatory T cells. Adv. Immunol. 108: 111-165. https://doi.org/10.1016/B978-0-12-380995-7.00004-5
  39. Roncarolo, M. G., S. Gregori, M. Battaglia, R. Bacchetta, K. Fleischhauer, and M. K. Levings. 2006. Interleukin-10-secreting type 1 regulatory T cells in rodents and humans. Immunol. Rev. 212: 28-50. https://doi.org/10.1111/j.0105-2896.2006.00420.x
  40. Papatriantafyllou, M. 2011. Tolerance: both natural and induced TReg talents needed. Nat. Rev. Immunol. 11: 500.
  41. Qureshi, O. S., Y. Zheng, K. Nakamura, K. Attridge, C. Manzotti, E. M. Schmidt, J. Baker, L. E. Jeffery, S. Kaur, Z. Briggs, T. Z. Hou, C. E. Futter, G. Anderson, L. S. Walker, and D. M. Sansom. 2011. Trans-endocytosis of CD80 and CD86: a molecular basis for the cell-extrinsic function of CTLA-4. Science 332: 600-603. https://doi.org/10.1126/science.1202947
  42. Gregori, S., K. S. Goudy, and M. G. Roncarolo. 2012. The cellular and molecular mechanisms of immuno-suppression by human type 1 regulatory T cells. Front. Immunol. 3: 30.
  43. Mellor, A. L., B. Baban, P. Chandler, B. Marshall, K. Jhaver, A. Hansen, P. A. Koni, M. Iwashima, and D. H. Munn. 2003. Cutting edge: induced indoleamine 2,3 dioxygenase expression in dendritic cell subsets suppresses T cell clonal expansion. J. Immunol. 171: 1652-1655. https://doi.org/10.4049/jimmunol.171.4.1652
  44. Coombes, J. L., K. R. Siddiqui, C. V. rancibia-Carcamo, J. Hall, C. M. Sun, Y. Belkaid, and F. Powrie. 2007. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J. Exp. Med. 204: 1757-1764. https://doi.org/10.1084/jem.20070590
  45. Sun, C. M., J. A. Hall, R. B. Blank, N. Bouladoux, M. Oukka, J. R. Mora, and Y. Belkaid. 2007. Small intestine lamina propria dendritic cells promote de novo generation of Foxp3 T reg cells via retinoic acid. J. Exp. Med. 204: 1775-1785. https://doi.org/10.1084/jem.20070602
  46. Ocadlikova, D., S. Trabanelli, V. Salvestrini, M. Ciciarello, C. Evangelisti, M. Lecciso, E. Sabattini, S. Righi, M. Piccioli, S. A. Pileri, R. M. Lemoli, and A. Curti. 2015. CD103 marks a subset of human CD34+-derived langerin＋ dendritic cells that induce T-regulatory cells via indoleamine 2,3-dioxygenase-1. Exp. Hematol. 43: 268-276. https://doi.org/10.1016/j.exphem.2014.12.007
  47. Paidassi, H., M. Acharya, A. Zhang, S. Mukhopadhyay, M. Kwon, C. Chow, L. M. Stuart, J. Savill, and A. Lacy-Hulbert. 2011. Preferential expression of integrin alphavbeta8 promotes generation of regulatory T cells by mouse CD103+ dendritic cells. Gastroenterology 141: 1813-1820. https://doi.org/10.1053/j.gastro.2011.06.076
  48. Goubier, A., B. Dubois, H. Gheit, G. Joubert, F. Villard-Truc, C. sselin-Paturel, G. Trinchieri, and D. Kaiserlian. 2008. Plasmacytoid dendritic cells mediate oral tolerance. Immunity 29: 464-475. https://doi.org/10.1016/j.immuni.2008.06.017
  49. Faunce, D. E., A. Terajewicz, and J. Stein-Streilein. 2004. Cutting edge: in vitro-generated tolerogenic APC induce CD8+ T regulatory cells that can suppress ongoing experimental autoimmune encephalomyelitis. J. Immunol. 172: 1991-1995. https://doi.org/10.4049/jimmunol.172.4.1991
  50. Harry, R. A., A. E. Anderson, J. D. Isaacs, and C. M. Hilkens. 2010. Generation and characterisation of therapeutic tolerogenic dendritic cells for rheumatoid arthritis. Ann. Rheum. Dis. 69: 2042-2050. https://doi.org/10.1136/ard.2009.126383
  51. Sato, K., N. Yamashita, N. Yamashita, M. Baba, and T. Matsuyama. 2003. Regulatory dendritic cells protect mice from murine acute graft-versus-host disease and leukemia relapse. Immunity 18: 367-379. https://doi.org/10.1016/S1074-7613(03)00055-4
  52. Gangi, E., C. Vasu, D. Cheatem, and B. S. Prabhakar. 2005. IL-10-producing CD4+CD25+ regulatory T cells play a critical role in granulocyte-macrophage colony-stimulating factor-induced suppression of experimental autoimmune thyroiditis. J. Immunol. 174: 7006-7013. https://doi.org/10.4049/jimmunol.174.11.7006
  53. Ferreira, G. B., C. A. Gysemans, J. Demengeot, J. P. da Cunha, A. S. Vanherwegen, L. Overbergh, T. L. Van Belle, F. Pauwels, A. Verstuyf, H. Korf, and C. Mathieu. 2014. 1,25-Dihydroxyvitamin D3 promotes tolerogenic dendritic cells with functional migratory properties in NOD mice. J. Immunol. 192: 4210-4220. https://doi.org/10.4049/jimmunol.1302350
  54. Adorini, L. 2003. Tolerogenic dendritic cells induced by vitamin D receptor ligands enhance regulatory T cells inhibiting autoimmune diabetes. Ann. N. Y. Acad. Sci. 987: 258-261. https://doi.org/10.1111/j.1749-6632.2003.tb06057.x
  55. Diana, J., Y. Simoni, L. Furio, L. Beaudoin, B. Agerberth, F. Barrat, and A. Lehuen. 2013. Crosstalk between neutrophils, B-1a cells and plasmacytoid dendritic cells initiates autoimmune diabetes. Nat. Med. 19: 65-73. https://doi.org/10.1038/nm.3042
  56. Li, Q., B. Xu, S. A. Michie, K. H. Rubins, R. D. Schreriber, and H. O. McDevitt. 2008. Interferon-alpha initiates type 1 diabetes in nonobese diabetic mice. Proc. Natl. Acad. Sci. U. S. A. 105: 12439-12444. https://doi.org/10.1073/pnas.0806439105
  57. Park, J. E., J. Jang, J. H. Choi, M. S. Kang, Y. J. Woo, Y. R. Seong, C. B. Choi, H. S. Lee, S. C. Bae, and Y. S. Bae. 2015. DC-Based Immunotherapy Combined with Low-Dose Methotrexate Effective in the Treatment of Advanced CIA in Mice. J. Immunol. Res. 2015: 834085.
  58. Zhang, L., J. Fu, K. Sheng, Y. Li, S. Song, P. Li, S. Song, Q. Wang, J. Chen, J. Yu, and W. Wei. 2015. Bone marrow CD11b(+)F4/80(+) dendritic cells ameliorate collagen-induced arthritis through modulating the balance between Treg and Th17. Int. Immunopharmacol. 25: 96-105. https://doi.org/10.1016/j.intimp.2015.01.014
  59. Ren, Y., Y. Yang, J. Yang, R. Xie, and H. Fan. 2014. Tolerogenic dendritic cells modified by tacrolimus suppress CD4(+) T-cell proliferation and inhibit collagen-induced arthritis in mice. Int. Immunopharmacol. 21: 247-254. https://doi.org/10.1016/j.intimp.2014.05.004
  60. Li, X., Y. Han, Q. Zhou, H. Jie, Y. He, J. Han, J. He, Y. Jiang, and E. Sun. 2016. Apigenin, a potent suppressor of dendritic cell maturation and migration, protects against collagen-induced arthritis. J. Cell. Mol. Med. 20: 170-180. https://doi.org/10.1111/jcmm.12717
  61. Yang, J., Y. Yang, Y. Ren, R. Xie, H. Zou, and H. Fan. 2013. A mouse model of adoptive immunotherapeutic targeting of autoimmune arthritis using allo-tolerogenic dendritic cells. PLoS One 8: e77729.
  62. Thomas, R., S. Street, N. Ramnoruth. 2011. Safety and preliminary evidence of efficacy in a phase I clinical trial of autologous tolerizing dendritic cells exposed to citrullinated peptides (Rheumavax) in patients with rheumatoid arthritis. Ann. Rheum. Dis. 70: 169.
  63. Benham, H., H. J. Nel, S. C. Law, A. M. Mehdi, S. Street, N. Ramnoruth, H. Pahau, B. T. Lee, J. Ng, G. B. ME, C. Hyde, L. A. Trouw, N. L. Dudek, A. W. Purcell, B. J. O'Sullivan, J. E. Connolly, S. K. Paul, K. A. Le Cao, and R. Thomas. 2015. Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients. Sci. Transl. Med. 7: 290ra87.
  64. Buckland, J. 2015. Rheumatoid arthritis: First-in-human phase I trial of DC immunotherapy for early RA. Nat. Rev. Rheumatol. 11: 443.
  65. Lim, D. S., M. S. Kang, J. A. Jeong, and Y. S. Bae. 2009. Semi-mature DC are immunogenic and not tolerogenic when inoculated at a high dose in collagen-induced arthritis mice. Eur. J. Immunol. 39: 1334-1343. https://doi.org/10.1002/eji.200838987
  66. Martin, E., C. Capini, E. Duggan, V. P. Lutzky, P. Stumbles, A. R. Pettit, B. O'Sullivan, and R. Thomas. 2007. Antigen-specific suppression of established arthritis in mice by dendritic cells deficient in NF-kappaB. Arthritis Rheum. 56: 2255-2266. https://doi.org/10.1002/art.22655
  67. Stoop, J. N., R. A. Harry, D. A. von, J. D. Isaacs, J. H. Robinson, and C. M. Hilkens. 2010. Therapeutic effect of tolerogenic dendritic cells in established collagen-induced arthritis is associated with a reduction in Th17 responses. Arthritis Rheum. 62: 3656-3665. https://doi.org/10.1002/art.27756
  68. Nielen, M. M., S. D. van, H. W. Reesink, R. J. van de Stadt, van der Horst-Bruinsma IE, M. H. de Koning, M. R. Habibuw, J. P. Vandenbroucke, and B. A. Dijkmans. 2004. Specific autoantibodies precede the symptoms of rheumatoid arthritis: a study of serial measurements in blood donors. Arthritis Rheum. 50: 380-386. https://doi.org/10.1002/art.20018
  69. Isaacs, J. D. 2010. The changing face of rheumatoid arthritis: sustained remission for all? Nat. Rev. Immunol. 10: 605-611. https://doi.org/10.1038/nri2804